Accessibility Menu
Chugai Pharmaceutical Stock Quote

Chugai Pharmaceutical (OTC: CHGCY)

$23.55
(-0.3%)
-0.07
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$23.55
Daily Change
(-0.3%) $0.07
Day's Range
$22.89 - $24.34
Previous Close
$23.55
Open
$22.89
Beta
0.52
Volume
128,803
Average Volume
181,616
Market Cap
77.5B
Market Cap / Employee
$23.55M
52wk Range
$19.5 - $31.26
Revenue
-
Gross Margin
0.70%
Dividend Yield
0.22%
EPS
$0.8
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Chugai Pharmaceutical Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CHGCY+3.38%+15.84%+2.98%+674%
S&P+14.5%+93.32%+14.09%+467%

Chugai Pharmaceutical Company Info

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Financial Health

General

Q2 2025YOY Change
Revenue$2.01B-1.0%
Gross Profit$1.40B-4.5%
Gross Margin69.63%-2.5%
Market Cap$85.80B46.7%
Market Cap / Employee$11.03M0.0%
Employees7.8K2.3%
Net Income$672.39M-6.3%
EBITDA$1.03B-4.4%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$3.44B40.6%
Accounts Receivable$2.19B0.9%
Inventory1.6K-1.3%

Liabilities

Q2 2025YOY Change
Long Term Debt$91.41M123.4%
Short Term Debt$0.00M0.0%

Ratios

Q2 2025YOY Change
Return On Assets18.51%-0.1%
Return On Invested Capital22.98%0.6%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$636.28M95.9%
Operating Free Cash Flow$821.10M78.6%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Earnings31.0328.7027.8132.4131.50%
Price to Book7.285.746.196.7324.82%
Price to Sales10.519.499.3310.7233.07%
Price to Tangible Book Value7.375.816.246.7924.47%
Price to Free Cash Flow TTM54.3841.5258.2354.50-17.94%
Enterprise Value to EBITDA65.0375.0771.1876.6654.09%
Free Cash Flow Yield1.8%2.4%1.7%1.8%21.87%
Return on Equity22.5%21.6%22.8%21.5%-3.32%
Total Debt$41.30M$69.34M$87.52M$91.41M123.39%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.